SIS
SMMT icon

Sound Income Strategies’s Summit Therapeutics SMMT Stock Holding History

Sound Income Strategies’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-410
Closed -$7.76K – 2103
2026
Q1 		$7.76K Sell
410
-595
-59% -$9.62K ﹤0.01% 1636
2025
Q4 		$17.1K Hold
1,005
– – ﹤0.01% 1218
2025
Q3 		$22.8K Buy
+1,005
New +$24.4K ﹤0.01% 778

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Sound Income Strategies's SMMT Position: Q2 2026 in Review

Sound Income Strategies sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 410 shares — an estimated $7.76K sold.

Sound Income Strategies first reported a position in SMMT in Q3 2025 and held it in 3 quarters. The position peaked at $22.8K in Q3 2025. 154 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Sound Income Strategies reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 410 Summit Therapeutics shares in Q2 2026, an estimated $7.76K.
  • Sound Income Strategies first reported a position in Summit Therapeutics in Q3 2025 and held it in 3 quarters.
  • Sound Income Strategies's Summit Therapeutics position peaked at $22.8K in Q3 2025.
  • 154 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.